Last reviewed · How we verify

LAS106521 — Competitive Intelligence Brief

LAS106521 (LAS106521) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase 4 (PDE4) inhibitor. Area: Immunology / Dermatology.

phase 3 Phosphodiesterase 4 (PDE4) inhibitor PDE4 Immunology / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

LAS106521 (LAS106521) — Almirall, S.A.. LAS106521 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LAS106521 TARGET LAS106521 Almirall, S.A. phase 3 Phosphodiesterase 4 (PDE4) inhibitor PDE4
Otezla APREMILAST Amgen marketed Phosphodiesterase 4 Inhibitor [EPC] PDE4 2014-01-01
Apremilast (CC-10004) Apremilast (CC-10004) Virginia Clinical Research, Inc. marketed Phosphodiesterase 4 (PDE4) inhibitor PDE4
Crisaborole ointment, 2% Crisaborole ointment, 2% Pfizer marketed Phosphodiesterase 4 (PDE4) inhibitor PDE4
Crisaborole Vehicle Crisaborole Vehicle Pfizer marketed Phosphodiesterase 4 (PDE4) inhibitor PDE4
CD0271 CD0271 Galderma R&D phase 3 PDE4 inhibitor PDE4
SPD503 (4 mg) SPD503 (4 mg) Shire phase 3 Phosphodiesterase 4 (PDE4) inhibitor PDE4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase 4 (PDE4) inhibitor class)

  1. Pfizer · 6 drugs in this class
  2. Shire · 3 drugs in this class
  3. Almirall, S.A. · 3 drugs in this class
  4. Arcutis Biotherapeutics, Inc. · 2 drugs in this class
  5. LEO Pharma · 2 drugs in this class
  6. ORA, Inc. · 1 drug in this class
  7. Tillotts Pharma AG · 1 drug in this class
  8. AbbVie (prior sponsor, Abbott) · 1 drug in this class
  9. Virginia Clinical Research, Inc. · 1 drug in this class
  10. Alfasigma S.p.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LAS106521 — Competitive Intelligence Brief. https://druglandscape.com/ci/las106521. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: